Gilead execs flag trial failures for Sjögrens and lupus drugs — while swapping out a favorite HIV program of top analyst – Endpoints News

Joining the barrage of companies digging headfirst into the newly opened KRAS mine, Novartis has announced a multiyear agreement with Sixth Element Capital and the UK Beatson Institute for Cancer Research to develop small molecules identified by the institute’s drug discovery unit.

The deal, whose specifics have not been disclosed, is the Swiss giant’s second KRAS collaboration since June, when Amgen electrified the field by revealing the first patient efficacy data from a therapy aimed at one of the most pervasive, oldest and evasive cancer mutation targets. In July, Novartis inked a low-money deal with Mirati Therapeutics.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.